Stocktoria
Clene Inc. CLNN
Clene Inc. (CLNN) earns a Piotroski F-score of 1/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $200,000 at a -13086.5% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 1/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| CLNN | Clene Inc. | 1/9 | — | — | — |
| LSTA | LISATA THERAPEUTICS, INC. | 1/9 | — | — | — |
| SER | Serina Therapeutics, Inc. | 2/9 | — | — | — |
| BFRG | BullFrog AI Holdings, Inc. | 1/9 | — | — | — |
| ABVC | ABVC BIOPHARMA, INC. | 3/9 | -13.52 | — | — |
| ATNM | Actinium Pharmaceuticals, Inc. | 2/9 | — | — | — |
| IXHL | Incannex Healthcare Inc. | 2/9 | — | — | — |
About Clene Inc.
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. It develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, the company markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. Clene Inc. is headquartered in Salt Lake City, Utah.
FAQ
Is CLNN financially healthy?
Clene Inc.'s Piotroski F-score is 1/9 (8–9 is excellent, 0–3 weak).
Does CLNN pay a dividend?
No, Clene Inc. does not currently pay a dividend.
How profitable is CLNN?
In FY2025, Clene Inc. had a net margin of -13086.5%.
What is the analyst price target for CLNN?
The average Wall-Street price target for Clene Inc. is $32.20, about 691.2% above the recent price, from 5 analysts.
Is CLNN a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Clene Inc.: a Piotroski F-score of 1/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.